drugset / Trial / NCT00638443

Lumbar Stenosis Outcomes Research (LUSTOR)

NCT00638443

Phase 4 Completed 29 enrolled University of Rochester Pfizer · collab
RandomizedCrossoverTriple-blindTreatment

Summary

The primary objective of the proposed pilot study is to determine the efficacy of pregabalin in prolonging the time to onset of pain and reducing the severity of pain associated with walking in patients with neurogenic claudication. Neurogenic claudication is defined as movement induced leg pain, numbness, heaviness, or vague discomfort in part or all of one or both legs provoked with walking and standing and relieved by sitting, squatting, or forward flexion posturing. The secondary objective is to examine the functional benefit of pregabalin with respect to improvement in duration and distance of walking.

Timeline

Start
2008-03
Primary completion
2010-03
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Diphenhydramine Unknown 12.5 mg
Subject Pregabalin Small molecule 150 mg